Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

The era of bioengineering: how will this affect the next generation of cancer immunotherapy?

Graciotti M, Berti C, Klok HA, Kandalaft L.

J Transl Med. 2017 Jun 19;15(1):142. doi: 10.1186/s12967-017-1244-2. Review.

2.

History and current state of immunotherapy in glioma and brain metastasis.

McGranahan T, Li G, Nagpal S.

Ther Adv Med Oncol. 2017 May;9(5):347-368. doi: 10.1177/1758834017693750. Epub 2017 Feb 1. Review.

3.

A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.

Inogés S, Tejada S, de Cerio AL, Gállego Pérez-Larraya J, Espinós J, Idoate MA, Domínguez PD, de Eulate RG, Aristu J, Bendandi M, Pastor F, Alonso M, Andreu E, Cardoso FP, Valle RD.

J Transl Med. 2017 May 12;15(1):104. doi: 10.1186/s12967-017-1202-z.

4.

The inflammatory cytokine IL-22 promotes murine gliomas via proliferation.

Liu X, Yang J, Deng W.

Exp Ther Med. 2017 Mar;13(3):1087-1092. doi: 10.3892/etm.2017.4059. Epub 2017 Jan 18.

5.

Dendritic cell based vaccination strategy: an evolving paradigm.

Filley AC, Dey M.

J Neurooncol. 2017 Jun;133(2):223-235. doi: 10.1007/s11060-017-2446-4. Epub 2017 Apr 22. Review.

PMID:
28434112
6.

Tumor Vaccines for Malignant Gliomas.

Srinivasan VM, Ferguson SD, Lee S, Weathers SP, Kerrigan BCP, Heimberger AB.

Neurotherapeutics. 2017 Apr;14(2):345-357. doi: 10.1007/s13311-017-0522-2. Review.

PMID:
28389997
7.

Insights into molecular therapy of glioma: current challenges and next generation blueprint.

Rajesh Y, Pal I, Banik P, Chakraborty S, Borkar SA, Dey G, Mukherjee A, Mandal M.

Acta Pharmacol Sin. 2017 May;38(5):591-613. doi: 10.1038/aps.2016.167. Epub 2017 Mar 20. Review.

PMID:
28317871
8.

The Safety of available immunotherapy for the treatment of glioblastoma.

Farber SH, Elsamadicy AA, Atik AF, Suryadevara CM, Chongsathidkiet P, Fecci PE, Sampson JH.

Expert Opin Drug Saf. 2017 Mar;16(3):277-287. doi: 10.1080/14740338.2017.1273898. Epub 2017 Jan 3. Review.

PMID:
27989218
9.

Checkpoints to the Brain: Directing Myeloid Cell Migration to the Central Nervous System.

Harrison-Brown M, Liu GJ, Banati R.

Int J Mol Sci. 2016 Dec 2;17(12). pii: E2030. Review.

10.

Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis.

Artene SA, Turcu-Stiolica A, Hartley R, Ciurea ME, Daianu O, Brindusa C, Alexandru O, Tataranu LG, Purcaru SO, Dricu A.

Onco Targets Ther. 2016 Nov 4;9:6669-6677. eCollection 2016.

11.

Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study.

Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H.

J Neurooncol. 2016 Dec;130(3):517-527. Epub 2016 Sep 13.

PMID:
27624914
12.

Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response.

Dejaegher J, Van Gool S, De Vleeschouwer S.

Immunotargets Ther. 2014 Mar 13;3:55-66. doi: 10.2147/ITT.S40121. eCollection 2014. Review.

13.

Cancer testis antigen and immunotherapy.

Krishnadas DK, Bai F, Lucas KG.

Immunotargets Ther. 2013 Apr 17;2:11-9. doi: 10.2147/ITT.S35570. eCollection 2013. Review.

14.

Prioritization schema for immunotherapy clinical trials in glioblastoma.

Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB.

Oncoimmunology. 2016 Feb 18;5(6):e1145332. doi: 10.1080/2162402X.2016.1145332. eCollection 2016 Jun. Review.

15.

Cancer Immunotherapy for Gliomas: Overview and Future Directions.

Hashimoto N.

Neurol Med Chir (Tokyo). 2016 Jul 15;56(7):355-60. doi: 10.2176/nmc.ra.2015-0310. Epub 2016 Apr 16. Review.

16.

Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma.

Vandenberk L, Garg AD, Verschuere T, Koks C, Belmans J, Beullens M, Agostinis P, De Vleeschouwer S, Van Gool SW.

Oncoimmunology. 2015 Sep 11;5(2):e1083669. eCollection 2016 Feb.

17.

Suppression of established hepatocarcinoma in adjuvant only immunotherapy: alum triggers anti-tumor CD8+ T cell response.

Wang B, Wang X, Wen Y, Fu J, Wang H, Ma Z, Shi Y, Wang B.

Sci Rep. 2015 Dec 9;5:17695. doi: 10.1038/srep17695.

18.

Immunomonitoring in glioma immunotherapy: current status and future perspectives.

Lamano JB, Ampie L, Choy W, Kesavabhotla K, DiDomenico JD, Oyon DE, Parsa AT, Bloch O.

J Neurooncol. 2016 Mar;127(1):1-13. doi: 10.1007/s11060-015-2018-4. Epub 2015 Dec 5. Review.

19.

Overview of current immunotherapeutic strategies for glioma.

Calinescu AA, Kamran N, Baker G, Mineharu Y, Lowenstein PR, Castro MG.

Immunotherapy. 2015;7(10):1073-104. doi: 10.2217/imt.15.75. Review.

20.

Engineering opportunities in cancer immunotherapy.

Jeanbart L, Swartz MA.

Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):14467-72. doi: 10.1073/pnas.1508516112. Review.

Supplemental Content

Support Center